2019 CYIR Finalized

31 ACUTE RESPIRATORY DISTRESS SYNDROME Catherine (Terri) L. Hough, MD MSc University of Washington Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine Seattle, WA MONDAY, MAY 20 ARDS ECMO FOR SEVERE ARDS Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, and Mercat A, for the EOLIA Trial Group, REVA, and ECMONet. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018; 378:1965-75. Summary Use of extracorporeal membrane oxygenation (ECMO) for patients with severe acute respiratory distress syndrome (ARDS) is increasing dramatically over the past 10 years, but the superiority of ECMO over conventional mechani- cal ventilation with low tidal volumes remains uncertain. Combes and colleagues addressed this question with “EOLIA,” an international randomized trial of 249 patients with severe ARDS, defined as a PaO2:FIO2 ratio of less than 50 mmHg for more than 3 hours or less than 80 for more than 6 hours, or an arterial partial pressure of carbon dioxide of at least 60 mmHg with a pH less than 7.25 for at least 6 hours. The primary outcome of the trial was mortality at 60 days, which was 35% in the ECMO group and 46% in the control group (p=0.09). Notably, 35 patients (28%) in the control group received ECMO after meeting crossover cri- teria; 60 day mortality was 57% among crossovers. Despite an absolute mortality reduction of 11% in the intention to treat analysis, conclusion of the study was that “60-day mortality was not significantly different lower with ECMO than with a strategy of conventional mechanical ventilation that included ECMO as rescue therapy.” Comments 1. Mortality for very severe ARDS remains high, both with and without treatment with ECMO. 2. ECMO trials in ARDS may be challenging to perform and inter- pret, with high numbers of patients excluded for early receipt of ECMO, and a significant proportion receiving ECMO in the control group as “crossovers.” 3. Patients receiving ECMO for very severe ARDS are at increased risk for thrombocytopenia and bleeding compared with conven- tional mechanical ventilation. 4. The EOLIA trial found an absolute decrease in 60-day mortality of 11% in patients randomized to ECMO (35% versus 46%); this was less than the expected mortality reduction of 20% and therefore the difference in mortality was concluded to be non- significant. 5. A post hoc Bayesian analysis of EOLIA (Goligher et al, JAMA 2018) and meta-analysis including EOLIA (Munshi et al, Lancet Respiratory Medicine 2019) both suggest that ECMO may be beneficial in reducing 60 day mortality in severe ARDS. ECCO2R FOR MODERATE ARDS Combes A, Fanelli V, Pham T, Ranieri VM on behalf of the ESICM Trials Group and the SUPERNOVA Investigators. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory dis- tress syndrome: the SUPERNOVA study. Intensive Care Medicine 2019 May;45(5):592-600 Summary The ARDS Network Investigators demonstrated that reduc- ing tidal volume to 4-6 cc/kg predicted body weight and plateau pressure to below 30 cm H2O improves survival of patients with ARDS. Achievement of these targets may be limited in some patients by severe respiratory acidosis. It has been postulated that there may be additional benefit in achieving “ultra-protective ventilation” by reducing tidal volume to 3-4 cc/kg predicted body weight and plateau pressure to below 25 cm H2O, but recognized that such an approach may be poorly tolerated. Extracorporeal carbon dioxide removal (ECCO2R) offers an approach to minimize respiratory acidosis by clearing carbon dioxide outside of the lungs. Combes and colleagues enrolled 95 patients with moderate ARDS in a feasibility and safety study to determine (1) if ECCO2R would allow patients with ARDS to achieve ultra-protective ventilation, and (2) the safety of this approach. Patients with PaCO2 > 60 mmHg were excluded from participation. By 24 hours, 82% of patients achieved ultra-protective ventilation. However, 39% of patients had adverse events, two of which were serious and attributed to ECCO2R. It appears that ECCO2R is feasible; a random- ized trial is needed to assess potential benefit. Comments 1. The benefits of lung protective ventilation may be extended by targeting even lower tidal volumes and plateau pressures than

RkJQdWJsaXNoZXIy MTM1ODMw